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Purpose. To present our results after short-term (1 month) intra-arterial infusion therapy of PGE1-alprostadil via a port system
implanted in the ipsilateral external iliac artery (EIA) in patients with severe rest pain. Methods. Ten patients with severe rest pain
were included. All patients showed extensive peripheral vascular disease below the knee. The tip of the catheter was introduced
via a retrograde puncture in the ipsilateral external iliac artery (EIA). The patients received intraarterial infusion of PGE1,2 0m g r
alprostadil daily, via the port catheter for 1 month. Results. Clinical success was evaluated according to subjective grading of
pain (group A signiﬁcant decrease, group B moderate decrease and group C no response). A signiﬁcant decrease of rest pain was
observedin8(groupA,80%)patients,amoderatedecreasein2(GroupB,20%),whereasnopatientsdemonstratedanysigniﬁcant
response. Both patients of group B had Buergers’ disease and continue to smoke during therapy. No peripheral thrombosis or
clinical deterioration was noticed. Conclusion. Intraarterial infusion of PGE1 alprostadil on a daily basis, using a port catheter into
the ipsilateral EIA, in selected patients with severe rest pain, seems to be very eﬀective, without any serious complications.
1.Introduction
Prostaglandin E1 has been reported to beneﬁt patients with
signiﬁcant peripheral vascular disease and limb threatening
ischemia [1]. The routes of infusion may be either intra-
venous or intra-arterial [2–4]. Previously Strecker et al. [3]
reported the use of an implantable port with its catheter
placed mainly (9 out of 10 patients) towards the periphery
of the leg for intra-arterial PGE1 infusion.
In the present study, we evaluate the same port in 10
patients with severe rest pain (Fontaine III), with its catheter
placed in retrograde fashion away of the periphery of the
leg, into the ipsilateral external iliac artery, after puncturing
the common femoral artery of the same leg. The rationale
of our study was to eliminate the risk of target vessel
thrombosis since EIA has a larger diameter than peripheral
arteries.
2.MaterialsandMethods
Ten patients (all men; age range: 34–71yrs) with severe rest
pain (Fontaine’s stage III) were included into the study.
Five of them had Buergers’ disease. The rest had extensive
peripheral atherosclerotic changes due to long standing
diabetes.
All patients showed a very poor run-oﬀ with total occlu-
sion of all three vessels slightly distally to trifurcation. Two
patients with Buergers’ disease had additional involvement
of the popliteal artery. No patient was suitable for by-pass
surgery because on selective arteriography no adequate distal
vessels were identiﬁed. All patients suﬀered from signiﬁcant
rest pain, and one type of amputation could be speculated
for them as the only potential treatment of choice.
Patients with signiﬁcantly restricted external iliac artery
inﬂow,unwillingtofollowadailyhospitalappointment,with2 The Scientiﬁc World Journal
signiﬁcant alterations in blood coagulations measurements,
heart failure, allergy to iodine contrast, PGE-1, or titanium
port, were excluded from this study. Additionally, stage IV
(ulcerations, osteomyelitis, or gangrene) patients were also
excluded, since the eﬀectiveness of the treatment was exclu-
sivelyaddressedforashortperiodinthesubgroupofpatients
suﬀering from severe rest pain.
Thecatheterswereplacedinaretrogradefashionintothe
external iliac artery via puncturing of the ipsilateral common
femoral artery. In our opinion, this change in location is
an important parameter for elimination of the potential
untowards eﬀects. The port system (PIPS, Cook Europe) was
implanted in the same manner as previouslydescribed [2, 3].
No systemic anticoagulation was administered.
After the implantation, PGE1 (20mcg alprostadil, Phar-
macia&UpJohn)dilutedin60mLnormalsalinewasinfused
daily over 60min, via the port, on a outpatient basis. Sub-
jective evaluation of the rest pain was determined at the end
of each week. Brachial-tibial index was correlated before and
at the completion of the treatment.
3. Results
The catheter port system could be successfully implanted
in all 10 patients without any signiﬁcant complications. All
of the patients experienced decrease of the pain from the
ﬁrst week which continued through the following weeks. 8
patients (group A) experienced signiﬁcant decrease of pain
and 2 (group B) moderate decrease. The patients of group B
had Buergers’ disease with occlusion of the popliteal artery
and no run-oﬀ peripherally.
No infection, migration, or leakage of the port occurred
during the followup. All catheters remained patent during
the month; this was related of course to the short period
of the treatment. No change in the brachial-tibial index oc-
curred in any patient.
4. Discussion
PGE1 mechanisms of action include peripheral vasodilata-
tion, improvement of microcirculation, and inhibition of
platelet aggregation [5, 6]. Intravenously or intra-arterial
infusion of PGE1 in patients with severe peripheral vascular
disease has been well documented to be a safe and eﬀective
method of treatment in this group of patients who have
a very limited—if any—choice of treatment [3, 7, 8].
Disadvantages of the intra-arterial infusion could be the
presence of local side eﬀects as rubor, swelling, and pain;
on the other hand, the easiest speculated intravenous route
needs a signiﬁcantly increased PGE1 dosage (up to four
times) in order to achieve the same to the arterial route
eﬀectiveness, since up to 90% of PGE1 undergoes metabolic
degradation by the ﬁrst passage from the lung parenchyma.
The need of such increased dosage makes the IV treatment
problematic especially in patients with borderline cardiac
or renal function [3–9]; by the intra-arterial application of
20µgo fP G E 1 (a quarter of the dose required for intravenous
delivery), systemic adverse eﬀects such as hypotension
(due to vasodilatation), lung edema, or cardiac failure are
signiﬁcantly decreased.
Using a port system, arterial access is continuous and
s a f e rc o m p a r e dt or e p e a t e da r t e r i a lp u n c t u r e s .I np r e v i o u s
reports, the risk of thrombotic complications when placed
(antegrade) in small diameter target vessels (profunda or
superﬁcial femoral arteries) suﬀering from vascular disease
was of signiﬁcant concern [3, 8]. This concern was the main
reason that led us to place the catheter in a retrograde
route with the ipsilateral external iliac artery to be the target
vessel. The rationale beyond that was that the implantation
to an artery with signiﬁcant ﬂow (EIA) may contribute to
longstanding patency. Infusion rate was 1cc per minute,
thus allowing the dilution to be distributed as a continuous
shower to the periphery within the blood circulation [10].
Theoretically a very small portion of the total amount of
PGE1 does not reach the extremity. Additionally we used in
ourprotocolthemaximumquantityPGE1 asdescribedinthe
literature. These two factors contribute additively to reach
maximum response and best clinical outcome.
The clinical result obtained in our patients enhances the
results of previous studies for good clinical short success.
Clinically important relief from rest pain was achieved in all
of the patients. The two patients who had moderate response
werepatientswithBuergers’diseasewhocontinuedtosmoke
during treatment. Smoking may reduce the eﬀectiveness of
that type of treatment in this speciﬁc subgroup of patients.
According to the literature many diﬀerent examinations
exist that can objectively document changes of perfusion in
the area of interest. Evaluation with transcutaneous PO2,
laser Doppler ﬂow, and volume ﬂow may show improve-
ments of microcirculation and limb perfusion and have been
adequately described [11, 12].
In conclusion, intra-arterial infusion of PGE1 via a port
in patients with rest pain has good short-term clinical
success by creating signiﬁcant peripheral vasodilatation. The
placement of the catheter tip into a large and quite “healthy”
artery and not near the occlusions may reduce or eliminate
the risk of arterial thrombosis or spasm. We think this is
an interesting new ﬁgure in this type of treatment. Further
studies with more patients may be needed to document these
observations.
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